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Elevated IgG4 in patient circulation is associated
with the risk of disease progression in melanoma
Panagiotis Karagiannis1,2, Federica Villanova1, Debra H Josephs1,3, Isabel Correa1, Mieke Van Hemelrijck4, Carl Hobbs5,
Louise Saul1,3, Isioma U Egbuniwe1, Isabella Tosi1, Kristina M Ilieva1,6, Emma Kent1, Eduardo Calonje7, Mark Harries8,
Ian Fentiman3, Joyce Taylor-Papadimitriou3, Joy Burchell3, James F Spicer3, Katie E Lacy1,7, Frank O Nestle1,
and Sophia N Karagiannis1,*
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of Oncology; Hematology and Stem Cell Transplantation; Hamburg, Germany; 3Department of Research Oncology; Division of Cancer Studies; Faculty of Life Sciences and
Medicine; King’s College London; Guy’s Hospital; London, UK; 4King’s College London; Faculty of Life Sciences and Medicine; Division of Cancer Studies; Cancer Epidemiology
Group; Guy’s Hospital; London, UK; 5Wolfson Center for Age-Related Diseases; King’s College London; London, UK; 6Breakthrough Breast Cancer Research Unit; Department of
Research Oncology; Guy’s Hospital; King’s College London School of Medicine; London, United Kingdom; 7Skin Tumor Unit; St. John’s Institute of Dermatology; Guy’s Hospital,
King’s College London and Guy’s and St Thomas’ NHS Trust; London, UK; 8Clinical Oncology; Guy’s and St. Thomas’s NHS Foundation Trust, London, UK
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Abbreviations: LDH, lactate dehydrogenase; CTC, circulating tumor cell; SD, stable disease; PD, progressive disease; Treg, regulatory
T cell; CRP, C-reactive protein; WBC, white blood cell count; ROC, receiver operating characteristic; AUC, area under the curve;
PFS, progression-free survival (PFS); OS, overall survival; HR, hazard ratio; CI, confidence interval; SNB, sentinel lymph node
biopsy; TMA, tissue microarray; PBMC, peripheral blood mononuclear cells
Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4C B cells in
inﬂammatory diseases and malignancies. We previously reported that IgG4 antibodies restrict activation of immune
effector cell functions and impair humoral responses in melanoma. Here, we investigate IgG4 as a predictor of risk for
disease progression in a study of human sera (n D 271: 167 melanoma patients; 104 healthy volunteers) and peripheral
blood B cells (n D 71: 47 melanoma patients; 24 healthy volunteers). IgG4 (IgG4/IgGtotal) serum levels were elevated in
melanoma. High relative IgG4 levels negatively correlated with progression-free survival (PFS) and overall survival. In early
stage (I–II) disease, serum IgG4 was independently negatively prognostic for progression-free survival, as was elevation of
IgG4C circulating B cells (CD45CCD22CCD19CCD3¡CD14¡). In human tissues (n D 256; 108 cutaneous melanomas; 56
involved lymph nodes; 60 distant metastases; 32 normal skin samples) IgG4C cell inﬁltrates were found in 42.6% of
melanomas, 21.4% of involved lymph nodes and 30% of metastases, suggesting inﬂammatory conditions that favor IgG4
at the peripheral and local levels. Consistent with emerging evidence for an immunosuppressive role for IgG4, these
ﬁndings indicate association of elevated IgG4 with disease progression and less favorable clinical outcomes. Characterizing
immunoglobulin and other humoral immune proﬁles in melanoma might identify valuable prognostic tools for patient
stratiﬁcation and in the future lead to more effective treatments less prone to tumor-induced blockade mechanisms.
Introduction
Malignant melanoma remains a potentially lethal skin cancer
despite emerging targeted therapies.1-4 Approximately 20–50% of
individuals diagnosed with early stage disease will develop metasta-
ses, yet current serum and histopathological evaluators are not
linked to disease mechanisms and thus may not accurately predict
the risk of disease recurrence.4 Prognosis largely relies on histologi-
cal evaluation of the primary lesion when available, including Bre-
slow thickness, ulceration and mitotic rate, together with
assessments of nodal involvement, all of which require invasive sur-
gical interventions.5 While sentinel node biopsy has been demon-
strated to provide valuable prognostic information, around 80% of
patients have a negative test but may develop long-term
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complications from surgery such as lymphoedema.6-8 Hence, alter-
native non-invasive indicators linked to a biological mechanism,
such as induction of immune suppression by melanoma cells,
would be highly valuable prognostic tools especially in early disease.
The only serological biomarker for melanoma recommended
in the American Joint Committee on Cancer guidelines is lactate
dehydrogenase (LDH).4 Elevated serum LDH levels are found in
patients with progressive disease manifesting at later stages of
melanoma. High serum LDH levels are indicative of active cell
necrosis associated with high tumor burden and are linked to
poor clinical responses to treatments.4,9,10 Serum biomarker can-
didates such as S-100B demonstrate high sensitivity and specific-
ity in advanced disease, but have not yet been applied in routine
clinical practice partly due to large variations among patient sam-
ples.11 Detecting circulating tumor cells (CTCs) may also be
indicative of active disease in patients with advancing and meta-
static tumors, signifying a worse clinical prognosis; however large
inter- and intra-patient variability in cancer cell antigen expres-
sion and large variations in CTC counts between blood draws
represent significant limitations.12-14 Regardless, markers that are
easily monitored (such as those in serum) and that may be
directly linked to early disease pathogenesis or progression are
desirable.15
Components of humoral immunity –including circulating
antibodies– are emerging as biomarkers for autoimmune, inflam-
matory or allergic conditions and malignant disease. Monitoring
antibodies in disease may provide 2 advantages: a) responses may
occur at early points of pathogenesis indicating likely future dis-
ease onset or recurrence; and b) B cell differentiation, class-
switching and antibody production are influenced by antigen rec-
ognition, or altered in response to inflammatory signals, with the
resulting antibodies constituting a convenient readout. Protein
array platforms like ‘immunosignature’ are now being developed
to monitor circulating antibodies, and applications in
Alzheimer’s disease and in cancer are emerging.16,17
Consistent with the notion that components of the humoral
response could be associated with malignancy, early data indi-
cated that IgG4 antibody subclass serum levels are dysregulated
in patients with melanoma.18 Pathogenic roles of IgG4 in inflam-
matory diseases and also in pancreatic cancers, extrahepatic chol-
angiocarcinomas, squamous cell carcinomas and melanomas
have also been described. Pathological features include elevated
or dysregulated IgG4 serum levels, tissue-resident IgG4C
immune cell infiltrates and associations with regulatory elements
such as regulatory T cells (Tregs).18-20 Additionally, correlations
with inadequate immune responses to vaccines and with immune
tolerance to allergen exposure following successful allergen
immunotherapies have been reported.
We previously reported that despite the presence of a tumor-reac-
tive mature humoral compartment in patients, production of IgG4
subclass antibodies may be favored inmelanoma and that IgG4may
contribute to defective antitumor immune responses.21-23 These
findings mandate a closer examination of the clinical significance of
this immunomodulatory antibody subclass, particularly its associa-
tion with disease progression. Here, in a cohort of patients and
healthy volunteers, we sought to examine the levels of circulating
IgG4 and IgG4C B cells and determine if there is an association
with disease progression in melanoma.
Results
Elevated IgG4 serum levels in patients predict the risk
of disease progression and survival
In order to investigate circulating IgG4 in malignant disease, we
analyzed sera from 167 patients with melanoma and from 104
healthy volunteers. Patient baseline characteristics are described in
Table S1 and the study design is described in
Figure 1. Significantly elevated serum IgG4 levels (IgG4/IgGtotal)
were detected in melanoma patients (median 0.031; 95%[CI]
0.036–0.051) as compared to healthy controls (median 0.017;
95%[CI] 0.026–0.042; P D 0.007; Figure 2A, left). The absolute
concentrations of IgG subclasses for each cohort are shown in Fig-
ure 2A (center and right). In order to study the association between
the levels of IgG4 and disease progression, clinical data from 167
patient sera were analyzed by stratifying patients into those with
stable disease (SD) and those with progressive disease (PD) during
the study period. In early disease (Stages I–II) patients with SD
during the study period displayed significantly lower serum levels
of IgG4 (IgG4/IgGtotal; median 0.023; 95%[CI] 0.024–0.044) as
compared to patients who developed PD (median 0.039; 95%[CI]
0.030–0.0805; P D 0.034; Figure 2B). For all disease stages
(Stages I–IV), patients with SD displayed significantly lower serum
levels of IgG4 (IgG4/IgGtotal; median 0.025; 95%[CI] 0.026–
0.039) than patients who developed PD (median 0.037; 95%[CI]
0.038–0.065; P D 0.0046; Figure 2B). To exclude any effects
introduced by infection or inflammation on IgG4 levels in this
study, we further examined potential correlations between IgG4
with C-reactive protein (CRP) and white blood cell count (WBC).
Neither WBC (r D 0.07: P D 0.527: n D 83) nor CRP (r D 0.14:
PD 0.331: nD 50) correlated with IgG4 levels in this study cohort
(Fig. 2C). Furthermore, in our patient cohort, the levels of serum
IgG4 (IgG4/IgGtotal) were not significantly different between non-
allergic individuals and those with a history of allergies or patients
with known drug intolerances (Fig. 2C).
Receiver operating characteristic (ROC) and area under the
curve (AUC) analyses 24 indicated that elevated IgG4 could pre-
dict the risk of melanoma progression in local disease (mean
AUC:0.65, P D 0.034 for Stages I–II) and overall (AUC:0.62, P
D 0.005 for Stages I–IV) (Figure S1A). These findings suggest a
prognostic value for IgG4 serum levels.
Since lactate dehydrogenase (LDH) is so far the only clini-
cally-used serum biomarker used to predict disease progression,4
the potential of patient sera IgG4 and LDH levels to predict clin-
ical outcomes were analyzed according to patient progression-
free survival (PFS) and overall survival (OS). Based on ROC
analysis, a threshold of 0.0345 for IgG4 was calculated via
Youden’s Index 25 (n D 91 in IgG4low, <0.034; n D 76 in
IgG4high, 0.034). Using this cutoff point, IgG4 had a sensitiv-
ity of 57.14% (95%[CI] 45.35%–68.37%) and a specificity of
68.89% (95%[CI] 58.26%–78.23%), giving a likelihood ratio
of 1.73.
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For analysis of LDH, sam-
ples were segregated into
groups according to normal
(240–480 mmol/L, n D 140)
and abnormal (>480 mmol/
L, nD 18) sera concentrations.
The thresholds for IgG4 and
LDH were subsequently used
to analyzed patient serum
IgG4 and LDH (hazard ratios,
HR) for PFS and OS
using multivariate analysis
(Fig. 2D). Kaplan-Meier
curve evaluations revealed that
IgG4high group displayed sta-
tistically significantly lower OS
(HR 95%[CI] 1.90 (1.17–
3.29); log-rank P D 0.0116)
and lower PFS (HR 95%[CI]
2.01 (1.34–3.35); log-rank P
D 0.0016) as compared to the
IgG4low group (Fig. 2D, top
panel). Patients with abnormal
LDH levels had lower OS
(HR 95%[CI] 7.71 (56.68–
723.3); log-rank P < 0.0001)
and lower PFS (HR 95%[CI]
6.93 (43.34–427.5); log-rank
P < 0.0001) as compared to
those with normal LDH
(Fig. 2D, bottom panel).
These data support the value
of both serum LDH and IgG4
in predicting overall disease
outcomes inmelanoma.More-
over, these findings are consis-
tent with an association
between immune evasion
mechanisms, such as those that
promote IgG4, with subse-
quent disease progression.
Age, sex and, when appro-
priate, stage-adjusted Hazard
Ratios (HR) and 95% Confi-
dence Intervals (CI) were cal-
culated for the risk of
progression-free survival. The
adjusted HR for IgG4 was
1.23 (95%[CI] 0.76–1.98)
versus 3.64 (95%[CI] 1.85–
7.19) for LDH in Stage I–IV
disease. In Stages III–IV, IgG4
had an adjusted HR of 0.99
(95%[CI] 0.55–1.77) whereas
LDH had an adjusted HR of
5.47 (95%[CI] 2.47–10.92).
Figure 1. Experimental study design, collection and processing of clinical samples. Cohorts of 171 melanoma
patients and 104 healthy volunteers were identiﬁed for evaluations of IgG4 and lactate dehydrogenase (LDH). IgG
subclass levels were measured using a standardized Luminex bead array assay (n D 171) and in the same samples,
LDH levels were analyzed through a diagnostic laboratory protocol (n D 158). *Researchers working on this study
were blinded to prevent bias; **Two independent medical professionals, not involved in the quantiﬁcation of IgG4
or LDH, evaluated patient information; ***Patients with co-morbidities that may inﬂuence IgG4 levels were
excluded from the analysis.
www.tandfonline.com e1032492-3OncoImmunology
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Figure 2. For ﬁgure legend, see next page.
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However, in the sera of patients with Stage I–II melanoma, IgG4
had an adjusted HR of 2.46 (95%[CI] 1.01–6.02) for predicting
progressive disease, whereas serum LDH had an adjusted HR of
12.29 (95%[CI] 1.18–128.00) (Table 1). In summary, these data
confirm the prognostic value of LDH and indicate that IgG4 serum
levels provide significant prognostic information in early stages (i.e.,
Stage I–II) of melanoma.
We next evaluated the prognostic potential of the combina-
tion of LDH and IgG4. When combined, these readouts had a
higher prognostic value (AUC:0.67; P D 0.0002) than LDH
(AUC:0.65; PD 0.0017) or IgG4 (AUC:0.60; PD 0.0227) indi-
vidually (Fig. S1B).
Elevated levels of peripheral blood IgG4C B cells predict the
risk of disease progression in Stage I–II melanoma
Since serum IgG4 levels were predictive of the risk of disease
progression in earlier stages (Stages I–II) of melanoma, we further
examined patient and healthy volunteer peripheral blood for the
presence of corresponding circulating IgG4C B cells. The fre-
quencies of circulating IgG4C peripheral blood B cells
(IgG4CCD45CCD22CCD19CCD3¡CD14¡) in melanoma
patients with melanoma compared to those from healthy volun-
teers were determined by flow cytometric analyses (Fig. 3A).
While there were no significant differences in the numbers of cir-
culating B cells (CD45CCD22CCD19CCD3¡CD14¡) in the
blood of patients with melanoma compared with healthy volun-
teers (Fig. 3A), the proportion of IgG4C cells in the peripheral
blood B cell compartment (CD45CCD22CCD19CCD3¡
CD14¡) of melanoma patients was significantly elevated (n D
47; median 0.50; 95%[CI] 0.47–0.73) compared with that of
healthy volunteers’ (n D 24; median 0.2; 95%[CI] 0.13–0.37;
Mann-Whitney-U-test; P D 0.003) (Fig. 3B). Furthermore, sig-
nificantly (Kruskal–Wallis one-way analysis of variance with
post-hoc Dunn’s test) higher frequencies of circulating IgG4C B
cells were detected in the blood of patients with Stage I–II
(median 0.50; 95%[CI] 0.44–0.72; P < 0.001; n D 24) and
Stage III–IV (median 0.40; 95%[CI] 0.41–0.89; P < 0.05;
nD23) disease than those of healthy volunteers (median 0.2;
95%[CI] 0.13–0.37; n D 24) (Fig. 3B, right).
The frequencies of circulating IgG4C B cells from patients
with melanoma diagnosed at different disease stages were further
analyzed to examine whether they could predict the risk of dis-
ease progression (Mann-Whitney-U-test; Fig. 3C). In the Stage
I–II patient cohort, patients with stable disease had a statistically
significantly lower frequency of IgG4C B cells than patients who
developed progressive disease (Stages I–II; AUC:0.81; P D
0.014; median of SD 0.30; 95%[CI] 0.17–0.56 vs. median of
PD 0.70; 95%[CI] 0.50–0.95). There were no statistically signif-
icant differences between SD and PD patient groups in Stages
III–IV (AUC:0.50; P > 0.05; median of SD 0.40; 95%[CI]
0.26–1.03 vs. median of PD 0.40; 95%[CI] 0.22–1.02) or in
Stages I–IV (AUC:0.63; P > 0.05; median of SD 0.30; 95%[CI]
0.30–0.69 vs. median of PD 0.50; 95%[CI] 0.44–0.88).
Thus, similar to the prognostic value of elevated serum IgG4
levels in early stage (Stage I–II) melanoma, these data suggest
that the IgG4C B cell compartment is elevated in the circulation
of patients as compared to healthy volunteers, and further, that
elevated IgG4C B cell frequencies are predictive of the risk of dis-
ease progression in Stage I–II melanoma.
IgG4C cell infiltration in cutaneous melanomas of different
thickness, disease stage and in distant metastases
In order to evaluate whether elevated serum IgG4 and circu-
lating IgG4C B cells in melanoma were also reflected by tumor
IgG4C cell infiltration, we performed immunohistochemical
analyses of tissue microarrays (n D 256) for the presence of tis-
sue-resident IgG4C cells. IgG4C cell infiltration was detected in a
proportion of melanoma tumors. Levels of infiltration were
found in melanoma skin lesions (n D 108), melanoma lymph
node metastases (n D 56) and distant organ metastases (n D 60)
but only low levels of infiltration were found in healthy skin
(nD32) specimens (examples in Fig. 4). IgG4 expression was
detected in 42.60% (19.45% high positivity) of melanoma skin
lesions, 21.40% (8.90% high positivity) of lymph node metasta-
ses and 30% (10% high positivity) of distant metastases. Low-
grade positivity was found in a smaller proportion (12.25%) of
healthy skin specimens (Fig. 5).
Similarly, IgG4C cell infiltrates were observed in local and
metastatic disease [(Stage I–II: 39.43% (16.90% high; 22.53%
Figure 2 (See previous page). Elevated serum levels of IgG4 in patient vs. healthy volunteer sera and IgG4 negatively correlates with risk of disease pro-
gression and survival. (A) Circulating IgG4 (IgG4/IgG4total) serum levels in melanoma patients (n D 167) were signiﬁcantly (P D 0.007) higher vs. IgG4 lev-
els in healthy volunteer sera (n D 104). Statistical analysis was performed by Mann-Whitney U-Test; lines represent medians and error bars indicate
interquartile range. Serum IgG subclass levels (ng/mL) for patients and healthy volunteer cohorts are shown in middle and right, respectively. (B) Com-
parative IgG4 serum level analyses among melanoma patients with subsequent stable (SD; n D 90) or progressive disease (PD; n D 77) in local (Stages I–
II) and metastatic (Stages III–IV) disease and in the whole cohort (all stages). IgG4 levels were elevated in patients with subsequent PD compared to
patients with SD during the study in the local disease setting (PD 0.034) and overall (P D 0.0046; Mann-Whitney-U-test). (C) Correlation analysis between
IgG4 and white blood cell count (WBC, r D 0.07: P D 0.527: n D 83; Spearman correlation, left) or C-reactive protein (CRP, r D 0.14: P D 0.331: n D 50;
Spearman correlation, middle) in melanoma patient blood. Circulating IgG4 (IgG4/IgG4total) serum levels between patient groups with or without known
allergies or known drug intolerances (right). (D) Evaluation of progression free survival (PFS) and overall survival (OS) in the melanoma patient cohort.
Based on ROC analysis, a threshold value of 0.034 for IgG4 (calculated via the Youden’s Index) was used to compare patient serum IgG4 and LDH hazard
ratios (HR) for the risk of progression-free survival (PFS) and overall survival (OS). The cohort was analyzed using multivariate analysis. For LDH, samples
were segregated into normal (240–480 mmol/L) and abnormal (>480 mmol/L) concentrations. Kaplan-Meier Curve evaluations revealed statistically sig-
niﬁcantly worse PFS (HR 95%[CI] 2.01 (1.34–3.35); log-rank P D 0.0016) and lower OS (HR 95%[CI] 1.90 (1.17–3.29); log-rank P D 0.0116) observed in the
IgG4high group compared to the IgG4low group. Patients with abnormal LDH levels had lower PFS (HR 95%[CI] 6.93 (43.34–427.5); log-rank P < 0.0001)
and lower OS (HR 95%[CI] 7.71 (56.68–723.3); log-rank P < 0.0001) vs. the LDH normal group.
www.tandfonline.com e1032492-5OncoImmunology
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low); Stage III–IV: 40% (6.67% high; 33.33% low)]. IgG4C cell
infiltrates were also found in skin tumor lesions of different thick-
nesses [(T1-T2: 38.88% (33.33% high; 5.55% low); T3:
37.29% (27.29% high; 10% low); T4: 46.03% (15.87% high;
15.87% low)] (Fig. 5). These findings may signify that IgG4-
attributed immunosuppressive functions may occur throughout
malignant disease, irrespective of skin tumor thickness.
Taken together, these data further support the value of cir-
culating IgG4 and IgG4C B cells as negative prognostic indi-
cators in melanoma. Furthermore, IgG4C infiltration in
melanoma lesions may indicate that immunomodulatory
mechanisms favoring IgG4-biased inflammation may also be
relevant in tumor microenvironments at different anatomic
sites.
Discussion
We have previously reported the presence of IgG4C infiltrating
cells in melanoma tumors and the functional contributions of
IgG4 in promoting tumor progression by impairing immunity. In
the same study, preliminary evaluations of circulating IgG4 in sera
from 33 melanoma patients a correlation between higher IgG4
levels and less favorable patient prognosis.22 We therefore wished
to elucidate whether antibody selection profiles featuring biased
production of IgG4 may be associated with disease progression
among patients with local or metastatic melanoma.
In a 167 patient cohort, we found higher overall circulating
IgG4 levels as compared to those from 104 healthy volunteer
sera. Consistent with our prior study and in concordance with
Table 1. Clinical characteristics of the patient cohort, hazard ratio prediction calculations and correlations with serum IgG4 and LDH levels. Patients were
categorized into 2 groups: those with low IgG4 levels (IgG4low: IgG4/IgGtotal <0.034; n D 91) and those with high IgG4 levels (IgG4high IgG4/IgGtotal 0.034;
n D 76), based on ROC analysis calculated via the Youden’s Index. For LDH, samples were segregated into normal (240–480 mmol/L, n D 140) and abnormal
(>480 mmol/L, nD18) concentrations. IgG4 predicted the risk of disease progression overall (combined Stages I–IV) as well as in local disease (Stages I–II). In
contrast, LDH had a signiﬁcant HR to predict the risk of disease progression overall (combined Stages I–IV). :^: Age, sex, and when appropriate stage adjusted
Hazard Ratios (HR) and 95% Conﬁdence Intervals (CI) for risk of disease progression
Patient Cohort IgG4<0.034 (nD91) IgG4 0.034 (nD76)
Mean age§ SD* 57 § 18 64 § 16
Sex
Male (%) 39 (42.85) 45 (59.21)
Female (%) 52 (57.15) 31 (40.79)
Mean Breslow § SD 2.53 § 2.24 3.36 § 2.32
Disease Stage (%)
I 28 (30.77) 7 (9.21)
II 18 (19.78) 26 (34.21)
III 24 (26.37) 24 (31.58)
IV 21 (23.08) 19 (25.00)
Ulceration (%)
None 51 (56.04) 30 (39.47)
Present 17 (18.68) 30 (39.47)
Unknown
HR:^ (95%CI)
Stage I–II
Stage III–IV
Stage I–IV
10 (25.28) 16 (21.06)
2.46 (1.01–6.02)
0.99 (0.55–1.77)
1.23 (0.76–1.98)
Patient Cohort LDH (240–480) (nD140) LDH >480 (nD18)
Mean age§ SD 59 § 18 64 § 15
Sex
Male (%) 70 (50.00) 11 (58.82)
Female (%) 70 (50.00) 7 (41.18)
Mean Breslow § SD 2.87 § 2.38 3.01 § 1.81
Disease Stage (%)
I 33 (23.57) 0 (0)
II 41 (29.29) 1 (5.56)
III 43 (30.71) 2 (11.11)
IV 23 (16.43) 15 (83.33)
Ulceration (%)
None 74 (55.04) 5 (27.78)
Present 38 (25.58) 7 (38.89)
Unknown HR:^ (95%CI)
Stage I–II
Stage III–IV
Stage I–IV
28 (19.38) 6 (33.33)
12.29 (1.18–128.00)
5.47 (2.74–10.92)
3.64 (1.85–7.19)
*SD: standard deviation.
:^ Age, sex and, when appropriate, stage adjusted Hazard Ratio (HR) and 95% Conﬁdence Intervals (CI) for risk of disease progression.
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Figure 3. For ﬁgure legend, see next page.
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published findings describing associations between inflammatory
pathologies and malignant diseases, we confirm that elevated
serum levels of IgG4 are negative predictors of progression-free
and overall survival in patients with melanoma. Furthermore,
our findings support the prognostic value of IgG4 in early stage
(Stage I–II) melanoma, where an unmet need exists for predictors
of disease progression.
Associations of elevated serum IgG4 levels with increased risk
of disease progression at early stages are supported by an elevated
circulating IgG4C B cell subset that is also predictive of the risk
of disease progression in early stages (Stage I–II). We speculate
that temporal and memory IgG4-biased immunity may be early
indicators of active immunosuppression and indicate worse clini-
cal outcomes, consistent with previous evidence that IgG4 anti-
bodies contribute to impairment of effective immune responses.
Therefore, immunomonitoring of circulating memory class-
switched IgG4C B cells may complement temporal immune
markers such as serum proteins, cytokines and autoantibodies.
From a clinical perspective, predicting which patients originally
diagnosed with localized melanoma will develop metastatic dis-
ease remains a clinical challenge. Novel indicators of disease pro-
gression are required to improve disease management, especially
at early disease stages. Presently, invasive interventions such as
sentinel lymph node biopsy (SNB) are used to elucidate disease
stage, to predict the risk of progressive disease and identify treat-
ment options. In the future, comparing the predictive value of
SNB with serum readouts, such as circulating IgG4, may permit
less intrusive clinical tools for patient management.
In our cohort, we confirm that the known serum biomarker
LDH is an independent prognostic indicator in melanoma.9,26
However, elevated serum LDH levels may be associated with a
range of non-neoplastic pathologies such as hemolysis, hepatitis,
myocardial infarction, or infections, yielding false-positive results
in melanoma.26 Elevated serum IgG4 levels are also described in
autoimmune pancreatitis, indicating that IgG4 may also be influ-
enced by biological mechanisms unrelated to malignancy,27
albeit only in a subset of patients. This limitation should be fur-
ther investigated in future studies evaluating the clinical utility of
serum IgG4 in melanoma.
Clinical practice has benefited by the companion diagnostic
test for BRAF V600 mutations, used to select patients who may
benefit from targeted pathway inhibitor drugs like vemurafe-
nib.28 Based on emerging evidence that elements of the immune
response play key roles in tumor surveillance and success of thera-
pies,29 it is possible that components of the immune system may
become the next important source of tissue prognostic indicators.
Infiltrating immune cells, including various B cell subsets in mel-
anoma 30 and other solid tumors, may be indicative of the
strength and nature of tumor immune responses and could be
linked to specific clinical outcomes. Here, we observe a promi-
nent IgG4C cell infiltrate in a proportion of melanomas across
tumor locations, tumor thicknesses and stages of disease.
Together with elevated IgG4 serum levels and increased circulat-
ing IgG4C B cells, this may indicate that immunosuppressive
mechanisms are present and active at both the peripheral and
local levels throughout disease stages. Although it was not feasible
here to associate these infiltrates with patient history or clinical
outcomes, in future studies IgG4C infiltrates may be examined
along with immune infiltrates associated with tumor-induced
suppressive mechanisms, such as Tregs.. Levels of IgG4C cell
infiltration may also be evaluated along with clinicopathological
features such as ulceration and mitotic rate, or combined with
other tissue markers such as S-100B.
Dysregulated antibody profiles are associated with a variety of
inflammatory pathologies, including malignant melanoma and
other types of cancer. The production of IgG4 subclass antibod-
ies is promoted in IL-10-driven alternative T helper type 2
(Th2)-biased immune conditions and in response to prolonged
antigen exposure. This results in class-switching and production
of IgG4, a subclass known to trigger ineffective Fc-mediated cell
activation due to distinctive conformation features.31,32 Mela-
noma tumor antigen-specific antibodies of the IgG4 isotype are
less potent at engendering effector cell–mediated tumor cell kill-
ing in vitro and in restricting tumor growth in vivo as compared
to IgG1. Importantly, both antigen-specific and nonspecific
IgG4 antibodies can impair IgG1-mediated tumoricidal func-
tions and this IgG4 blockade is mediated through interfering
with IgG1 engaging activity at Fcg receptors.22,33 Although
tumor cell-reactive IgG4 antibodies have been detected both in
patient circulation and in cutaneous melanoma lesions, Fc recep-
tor binding and blockade of effector cell activation appears to
form a key aspect of the immunomodulatory functions of IgG4.
Figure 3 (See previous page). Increased frequencies of peripheral blood IgG4C B cells from melanoma patients compared to healthy volunteers. (A)
Representative cytoﬂuorimetric dot plots and ﬂow cytometry gating strategy for evaluation of the circulating IgG4C B cell compartment. Lymphoid cells
were gated according to their FSC-A and SSC-A properties and viable CD45C were selected and cell doublets excluded using FSC-A and FSC-H dot plots.
CD3¡CD14¡ cells were selected and B cells identiﬁed as CD19CCD22C cells (top panel). Although the overall number of circulating B cells did not differ
signiﬁcantly between melanoma patients and healthy volunteer samples (lower panel, left for % of total PBMCs and numbers of B cell events), the IgG4C
cells were selected from the CD45CCD22CCD19CCD3¡CD14¡ cell compartment. Representative dot plots depicting IgG4C
(CD45CCD22CCD19CCD3¡CD14¡) peripheral B cells from PBMCs of a healthy volunteer (middle) and of a melanoma patient (right) (lower panel). (B)
Left and Middle: The number (left) and frequency (middle) of the IgG4C peripheral B cell compartment (based on counted
CD45CCD22CCD19CCD3¡CD14¡ cells) of 24 healthy volunteer and 47 melanoma patient samples showed statistically signiﬁcantly higher levels of
IgG4C B cells in the patient group (Mann-Whitney-U-test; P D 0.01; P D 0.003); Right: IgG4C B cell frequencies differed signiﬁcantly between Stages I–II (n
D 24; *** P <0.001) or Stage III–IV (nD 23; * P<0.05) vs. healthy volunteers (n D 24). Statistical analysis was performed by Kruskal-Wallis one-way analysis
of variance with post-hoc Dunn’s test; lines represent medians and error bars indicate interquartile range. (C) Frequency of circulating IgG4C B cells from
patients with local (Stages I–II) or metastatic (Stages III–IV) melanoma and correlation with risk of disease progression. Statistical analysis was performed
by Mann-Whitney-U-test; lines represent medians and error bars indicate interquartile range. Corresponding ROC analyses are depicted directly under-
neath each column graph. In the Stage I–II patient cohort, patients with stable disease had a signiﬁcantly lower frequency of IgG4C B cells vs. patients
with progressive disease (*P D 0.014). For this cohort, a median AUC of 0.81 was calculated by ROC analysis.
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This Fc receptor blockade mechanism
may operate in conjunction with recog-
nition and occupancy of tumor antigens
on the surface of cancer cells by IgG4,
hindering engagement of potentially
tumoricidal antibodies. Consistent with
immune tolerance and inhibition of
antitumor antibody functions described
as features of IgG4, humoral immune
profiles skewed toward IgG4 expression
correlate with low protective efficacy of
some HIV vaccination approaches.34,35
Immune bias toward IgG4 is also associ-
ated with disease pathology in IgG4-
related inflammatory diseases and with
immune suppression in cancers, such as
pancreatic and squamous cell carcino-
mas and extrahepatic cholangiocarcino-
mas.18-20,36 Antibodies of the IgG
subclass are also associated with patient
responses to allergen immunothera-
pies.37-39 Manifestations of IgG4
humoral immune response bias include:
1) elevated or dysregulated IgG4 serum
levels; 2) the presence of IgG4C
immune cell infiltrates in affected tis-
sues; and 3) associations of tissue-resi-
dent IgG4C cells with regulatory cells
such as FoxP3C Tregs. In concordance
with previous reports, our data here pro-
vide rationale for further evaluation of
dysregulated IgG4 antibody immunity
as a prognostic indicator in melanoma,
perhaps along with other immunoregu-
latory components. Clinical applica-
tions in regards to other malignant and
inflammatory diseases or in monitoring
host responses to vaccination and
immunotherapies may also warrant
future investigation.40 Various compo-
nents of the humoral immune system,
including circulating antibodies, have
been widely studied in relation to auto-
immune, inflammatory, allergic and
malignant diseases. In order to assess
early disease, circulating antibodies
monitored via microarray-based tech-
nologies could complement other bio-
markers, such as circulating antigens,
perhaps combined using emerging and
novel bioinformatics tools.41-43
Monitoring of dysregulated compo-
nents of host immune surveillance,
such as IgG4 or cell subsets that indi-
cate immunosuppression,44,45 could
help predict non-responders to
Figure 4. IgG4C cell inﬁltrates are detected in melanoma skin tumors. A tissue microarray (TMA; Bio-
Max, n D 256) consisting of melanoma skin tumors (n D 108), melanoma lymph nodes metastases (n
D 56), distant organ metastases (n D 60) and healthy skin (n D 32) specimens (top panel) was exam-
ined for the presence of IgG4 by immunohistochemistry. IgG4 positive inﬁltrates were detected by
alkaline phosphatase (in red, selected areas shown by black arrows) and sections were counterstained
in hematoxylin (in blue). Representative images of IgG4 immunohistochemical staining for IgG4C inﬁl-
tration revealed positive staining in skin lesions (top and second panels), lymph node and distant
metastases (third panel), while staining was less frequent in healthy skin (bottom panel). Black bar rep-
resents 800 mm (third bottom right panel).
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immunotherapies including monoclonal antibodies. Simulta-
neous serological, diagnostic and immunological readouts may
also be envisaged, based on the premise that multiple markers
each with a unique sensitivity and specificity combined using an
appropriate algorithm may harbor robust diagnostic or prognos-
tic potential.43 In concordance, we found that combined analy-
sis of serum LDH and IgG4 levels had improved predictive
value for disease progression. Combined clinical tools, such as
radiological assessments along with the clinically-used serum
LDH at baseline, have been reported to improve predictions of
patient outcomes following therapy with the monoclonal anti-
body bevacizumab.46 Thus, assessments of multiple parameters
may provide better prognostic utility for patient management in
the future. Larger clinical studies are required to identify and
validate more reliable combinations of disease biomarkers,
including IgG4 in melanoma, to derive improved models of
personalized medicine.
The immunological mechanisms that govern the nature of
humoral responses in cancer remain only partly elucidated, includ-
ing those underlying biased IgG4 subclass expression in patient
Figure 5. IgG4C cell inﬁltration is higher in melanoma skin tumors, melanoma lymph nodes metastases, and distant organ metastases, compared to
healthy skin. Top panel: Evaluation of tissue microarray (TMA) sections for frequency of IgG4C cell inﬁltration in melanoma tissues in skin, lymph node
metastases and distant metastases vs. healthy skin (Pie charts represent % of total numbers). Middle panel: In skin lesions (n D 108), IgG4C inﬁltration is
found in early (Stage I–II) and metastatic (Stage III–IV) disease. Lower panel: In melanoma skin lesions, IgG4C cell inﬁltration is demonstrated across differ-
ent melanoma skin tumor thicknesses (T1-T4). Analyses were performed by 2 independent researchers to identify the density of inﬁltration per high
power ﬁeld using the following criteria: “negative” D 0% inﬁltration; “low”< 25% inﬁltration; “high”> 25% inﬁltration.
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circulation and melanoma tumors. Although IgE and IgG4 are
promoted by Th2 conditions, preferential expression of IL-10 in
melanoma tumors could polarize a classical Th2-type immunity
toward IgG4.47,48 At early phases of carcinogenesis, initial stress
signals and release of mediators such as IL-25, TSLP and IL-33 by
epithelial cells in the skin may drive IL-4 production and perhaps
favor IgE which may confer protection.49–51 However, the persis-
tent production of IL-10 by tumor cells and by tumor-promoted
Tregs and macrophages may skew Th2 immunity in favor of IgG4
at early and late stages of disease manifestation. In this sense, higher
than normal IgG4 levels particularly in early stage melanoma may
signify active immunosuppressive forces already in operation.
In the future, it can be envisaged that antibodies less prone to
IgG4 immune impairment, treatments that counteract IL-10-
driven inflammation, or interventions that promote classical
rather than alternative Th2 immunity could help refocus antitu-
moral immune signals. Strategies may include induction of pro-
tective Th2 responses that could perhaps drive de novo IgE or
class switching from IgG4 to IgE.52-56 Alternatively, exploiting
the potent functions of IgE class antibodies directed against
tumor antigens may harness the intrinsic capacity of IgE for
immune surveillance in Th2-biased tissue environments such as
melanoma and other solid tumors.57,58 Taken together with
emerging insights into the humoral arm of immunity in cancer,
elucidating the significance and mechanisms of immunoglobulin
subclasses may point to therapeutic strategies less prone to
tumor-associated immune impairment.
In summary, we confirm that IgG4, a purported indicator of
immunosuppressive forces in melanoma is elevated in the circula-
tion of melanoma patients, is associated with worse clinical out-
comes, and is a negative prognostic indicator at early stages of
melanoma. Broader applications for IgG4 monitoring may be
complimented by other clinical tools, such as LDH, or upon
incorporation into immune profiling algorithms. Larger prospec-
tive studies will ascertain the clinical significance of IgG4, per-
haps along with other immunoglobulin or immune cell
signatures, in facilitating more accurate prediction of progressive
disease. This may pave the way for improved patient stratification
and optimal personalized therapies.
Materials and Methods
Sample collection
Human specimens were collected with written informed con-
sent (approved by the Guy’s Research Ethics Committee, Guy’s
and St. Thomas’ NHS Trust, UK). Patients were staged and clas-
sified according to the American Joint Committee on Cancer
Melanoma Staging and Classification criteria.4 Patients with
Stage I–II melanoma had regional disease with no lymph node
involvement or any other metastases; patients with Stage III mel-
anoma had tumor cells detected in at least one lymph node;
patients with Stage IV melanoma had distant metastases. Disease
was staged by means of physical examinations by a trained
dermatologist and verified by histopathological evaluations. The
extent of disease was also assessed by means of appropriate
clinical imaging tools such as PET-CT or CT. The study end-
points were progression-free survival and overall survival.
IgG subclass and LDH analyses in human sera
Luminex bead array assay kits for assessments of IgG4 subclass
antibodies in human sera were used according to the man-
ufacturers’ instructions. Data analyses to assess IgG subclass anti-
bodies were conducted using Milliplex MAP (Millipore, Cat.-
No HGAMMAG-301K) and data were acquired and analyzed
using FlexMap3D (Luminex Corporation). LDH serum levels
were measured at the central laboratories of the associated hospital.
Immunohistochemical evaluations
Tissue microarrays (TMA; BioMax, n D 256) of paraffin
embedded sections were cut at 6–8 mm thickness on a micro-
tome (Leica) and dried overnight at 60C. Prior to staining, sec-
tions were deparaffinized in xylene for 20 min and rehydrated by
serial incubations in alcohol. Heat-induced antigen retrieval was
performed in a 95C water bath using a citric acid solution (pH
D 6.0). Sections were subsequently blocked with human FcR
blocking reagent (Miltenyi Biotec; Cat-No: 130-059-90) accord-
ing to the manufacturer’s instructions and stained using a mouse
anti-human IgG4 antibody (BD Biosciences; Cat-No:555881),
followed by a rabbit anti-mouse IgG antibody conjugated to bio-
tin (DAKO; Cat-No: E035401-2). IgG4C cell infiltrates were
detected using the VECTOR Red Alkaline Phosphatase Substrate
Kit with levamisole (Vector Labs; Cat-No: SK-5100). All sections
were mounted in DPX mounting solution and analyzed on a
Zeiss Axiophot microscope using a 10x magnification lens (Carl
Zeiss) and NIS-Elements imaging software (Nikon). Cell density
of sections stained for IgG4C B cell infiltration was evaluated by
2 independent researchers to identify the occupancy of infiltra-
tion per high power field (10x) using the following criteria for
occupancy: “negative” D 0% infiltration; “low” < 25% infiltra-
tion; and “high” > 25% infiltration.
Peripheral blood cell isolation and cytofluorimetric analysis
of circulating IgG4C B cells
Peripheral blood mononuclear cells (PBMC) were isolated
from venous blood by density centrifugation over Ficoll-Paque
Plus (GE Healthcare; Cat-No: 17144003). Cells were placed in
RPMI 1640 medium (Life Technologies; Cat-No:31870-025)
with 11.25% human serum albumin (Gemini Bio-Products,
West Sacramento; Cat.-No: 800-125P), frozen in 10% DMSO
(Sigma; Cat.-No: D2650) and stored in liquid nitrogen. Prior to
analyses, cells were thawed and stained with fluorophore-conju-
gated antibodies against the following surface markers (BD Bio-
sciences; Cat.-No: 560777, 562859, 562653, 641397,555947,
555881): CD45, CD22, CD19, CD3, CD14, IgG4. Prior to
use, the anti-IgG4 antibody was pre-labeled with R-phycoery-
thrin (Innova Bioscience; Cat-No: 703-0030) following the man-
ufacturer’s instructions. Dead cells were excluded by staining
with LIVE/DEAD Fixable Dead Cell Stains (Life Technologies;
L23105). Samples were subsequently acquired on a 5-laser SORP
Fortessa (BD Bioscience) flow cytometer and data analyzed using
the same instrument application settings across different
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experiments. IgG4C cells were analyzed based on gating with an
isotype control. All sample analyses were performed using FlowJo
software (Treestar).
Statistical analyses
Human serum and cell populations were assessed for normal
Gaussian distribution with D’Agostino and Pearson omnibus nor-
mality test, followed by Kruskal–Wallis one-way analysis of vari-
ance with post-hoc Dunn’s test. For comparisons between 2
groups and where populations were not normally distributed (ana-
lyzed by D’Agostino’s K-square test for normality) statistical signif-
icance between groups was calculated using the Mann-Whitney-U-
test. For correlation and patient survival analyses, Spearman and
Mantel-Cox analyses were applied. Receiver Operating Character-
istic (ROC) analyses and area under the curve (AUC) analyses
were performed to assess the prognostic capacity of IgG4 in
patient sera. The prognostic capacity of LDH and IgG4 combined
serum tests was evaluated by applying a ROC analysis and calcu-
lating the area under the curve (AUC3). Threshold values were
calculated via the Youden’s Index25 to compare patient serum
IgG4 with LDH and determine hazard ratios (HR) for the risk of
progression free survival (PFS) and overall survival (OS). The
cohort was analyzed using multivariate analysis. The maximum
follow-up (from time of venipuncture to the last documented clin-
ical visit) was 4.82 years with a median follow-up for overall sur-
vival of 2.08 years for LDH and 2.04 years for IgG4. The
correlation between IgG4 and C-reactive protein, between IgG4
and white blood cell count and between IgG4 and breslow thick-
ness were calculated using a Spearman correlation as the cohorts
were not normally distributed.
Comparative IgG4 serum level analyses among melanoma
patients with subsequent stable (SD) or progressive disease (PD)
were conducted. Patients were segregated into: a) those with stable
disease (neither progressive disease nor subsequent relapse during
study period); and b) those with progressive disease (either active
progressing disease monitored by imaging tools such as PET-CT,
or subsequent relapse during study period). Patients could only be
up-staged from their initial staging during the study period.
Error bars in all figures represent standard error of mean
(SEM). All statistical tests were performed using GraphPad Prism
Version 6, with the exception of the calculation of hazard ratio
(HR), which was performed using the SAS software version 9.2
(SAS Institute Inc.). All reported P values are derived from 2-
sided comparisons with values of less than 0.05 considered to
indicate statistical significance.
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